Cervomed Inc. quarterly report, Q2 FY2017

Business context and reporting period

The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2017—not a filing identifying Cervomed Inc. as the registrant. Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), intended to improve cancer-treatment effectiveness by addressing tumor hypoxia. The filing reports no product revenue.

Financial performance and position

Quarterly net income was driven by a $23.39 million noncash gain from remeasuring warrant liabilities, primarily following a decline in the common-stock price; it does not reflect operating profitability. Six-month results included $10.23 million of warrant-related expense and $2.87 million of other financing expense. Revenue and profit margins are not meaningful given the company’s pre-revenue status and operating losses.

At June 30, cash and cash equivalents were $7.41 million and a certificate of deposit was $10.00 million. Working capital was negative $11.8 million, partly reflecting a $24.76 million warrant liability. Total assets were $33.91 million; total liabilities were $32.74 million; stockholders’ equity was $1.17 million. Convertible debt principal totaled $2.43 million and was presented as current on the balance sheet. The company reported a $68.44 million accumulated deficit.

Material changes versus prior comparable periods

• Quarterly operating loss narrowed from $3.80 million in 2016 to $2.98 million in 2017, while net results shifted from a $3.81 million loss to $20.39 million income due to the warrant fair-value gain.
• For the first six months, operating loss declined from $10.02 million to $5.55 million and net loss narrowed from $10.03 million to $8.25 million. R&D and G&A expenses also fell, including because 2016 G&A included reverse-merger costs.
• Operating cash use was $6.16 million versus $7.49 million in the first half of 2016. A $22.09 million financing inflow from the March 2017 private placement supported the $5.86 million increase in cash; the company also placed $10 million in a certificate of deposit.
• In March, the company raised approximately $22.1 million net through Series A preferred stock and warrants. The preferred stock carries an 8% cumulative dividend payable in common shares. Related warrants are liability-classified and measured at fair value.

Outlook, risks, contingencies and unusual items

• Management estimated that cash and the certificate of deposit would fund operations through March 2018, but said substantial additional financing would be needed. The filing states that recurring losses raise substantial doubt about the company’s ability to continue as a going concern.
• A proposed offering of up to $20 million of Series B preferred stock and warrants had stockholder approval, but completion was uncertain. The company warned that inability to raise funds could force it to delay, reduce or stop development, pursue collaborations or strategic alternatives, or cease operations.
• NASDAQ notified the company on May 26, 2017 that it did not meet listing standards for market value of listed securities and also failed the stated alternative equity and earnings tests. It had until November 20, 2017 to regain compliance with market-value or stockholders’-equity requirements.
• Management expected R&D spending to rise as TSC development advances. The Phase 2 GBM study reported a favorable signal, including a stated 37% improvement in two-year overall survival versus controls; the company described a possible Phase 3 focus on inoperable patients, with an estimated enrollment of about 230. These are company-reported findings and plans, not established efficacy or approval.
• Further pancreatic cancer and brain-metastasis studies were subject to funding or collaboration. Stroke-trial planning was ongoing. A July 5, 2017 CRO services agreement was disclosed as a subsequent event.
• A former executive’s arbitration claim seeks unspecified damages and other relief. The company considers it without merit, but said it could not predict the outcome or possible loss.

Important facts for investors to verify

• Confirm the registrant identity: the supplied filing names Diffusion Pharmaceuticals Inc., while the request metadata names Cervomed Inc.
• Assess cash runway and financing access, including the status and actual proceeds of the proposed Series B offering and NASDAQ compliance.
• Review the warrant-liability valuation and its effect on reported earnings, including the substantial Level 3 estimate and share-price sensitivity.
• Check debt maturities and terms, preferred-stock dividends, conversion and liquidation rights, and potential dilution from outstanding warrants and securities.
• Track TSC trial design, funding, enrollment and regulatory progress; independently evaluate the reported Phase 2 results and proposed Phase 3 assumptions.
• Monitor the arbitration matter and any material change in the company’s liquidity or going-concern assessment.